Literature DB >> 19615973

3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection.

Hongbin Yan1, Rhonda KuoLee, Kha Tram, Hongyu Qiu, Jianbing Zhang, Girishchandra B Patel, Wangxue Chen.   

Abstract

3',5'-Cyclic diguanylic acid (cdiGMP) is emerging as a universal bacterial second messenger in regulating bacterial growth on surfaces. It has been recently shown that cdiGMP stimulates innate immunity and enhances antigen-specific humoral and cellular immune responses. We herein report that intranasal (i.n.) administration with cdiGMP induces an acute but transient inflammatory response and activation of dendritic cells in the lungs. Moreover, i.n. immunization of mice with pneumococcal surface adhesion A (PsaA) in conjunction with cdiGMP elicited strong antigen-specific serum immunoglobulin G (IgG) and secretory IgA antibody responses at multiple mucosal surfaces. More importantly, the immunized mice showed significantly reduced nasopharyngeal Streptococcus pneumoniae colonization. These results, for the first time, provide direct evidence for the induction of protection against mucosal bacterial infections by cdiGMP as an adjuvant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19615973     DOI: 10.1016/j.bbrc.2009.07.061

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

Review 1.  Cyclic diguanylate signaling in Gram-positive bacteria.

Authors:  Erin B Purcell; Rita Tamayo
Journal:  FEMS Microbiol Rev       Date:  2016-06-26       Impact factor: 16.408

2.  Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine.

Authors:  Shifeng Wang; Yuhua Li; Huoying Shi; Giorgio Scarpellini; Ascencion Torres-Escobar; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2010-05-17       Impact factor: 3.441

3.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Authors:  Melissa C Hanson; Monica P Crespo; Wuhbet Abraham; Kelly D Moynihan; Gregory L Szeto; Stephanie H Chen; Mariane B Melo; Stefanie Mueller; Darrell J Irvine
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

Review 4.  Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants.

Authors:  Thomas W Dubensky; David B Kanne; Meredith L Leong
Journal:  Ther Adv Vaccines       Date:  2013-11

5.  An Improved Strategy for the Chemical Synthesis of 3',5'-Cyclic Diguanylic Acid.

Authors:  Andrzej Grajkowski; Mayumi Takahashi; Tomasz Kaczyński; Suresh C Srivastava; Serge L Beaucage
Journal:  Curr Protoc Nucleic Acid Chem       Date:  2019-04-10

6.  Stimulation of innate immunity by in vivo cyclic di-GMP synthesis using adenovirus.

Authors:  Benjamin J Koestler; Sergey S Seregin; David P W Rastall; Yasser A Aldhamen; Sarah Godbehere; Andrea Amalfitano; Christopher M Waters
Journal:  Clin Vaccine Immunol       Date:  2014-09-17

Review 7.  Interferons and viruses: an evolutionary arms race of molecular interactions.

Authors:  Hans-Heinrich Hoffmann; William M Schneider; Charles M Rice
Journal:  Trends Immunol       Date:  2015-02-20       Impact factor: 16.687

Review 8.  Cyclic di-GMP: the first 25 years of a universal bacterial second messenger.

Authors:  Ute Römling; Michael Y Galperin; Mark Gomelsky
Journal:  Microbiol Mol Biol Rev       Date:  2013-03       Impact factor: 11.056

9.  A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain.

Authors:  Greg Harris; Rhonda Kuo Lee; Christopher K Lam; Gregory Kanzaki; Girishchandra B Patel; H Howard Xu; Wangxue Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

10.  In Vivo Synthesis of Cyclic-di-GMP Using a Recombinant Adenovirus Preferentially Improves Adaptive Immune Responses against Extracellular Antigens.

Authors:  Fadel S Alyaqoub; Yasser A Aldhamen; Benjamin J Koestler; Eric L Bruger; Sergey S Seregin; Cristiane Pereira-Hicks; Sarah Godbehere; Christopher M Waters; Andrea Amalfitano
Journal:  J Immunol       Date:  2016-01-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.